Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 3/2015

01.09.2015 | short review

Indolent lymphoma at ASH 2014: new kids on the block (iDrugs)

verfasst von: MD Thomas Nösslinger

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten
share
TEILEN

Abstract

Recent clinical data presented at the annual meeting of the American Society of Hematology support the potential use of chemotherapy-free combinations in first-line treatment of follicular lymphoma. Rituximab maintenance seems to be very useful after autologous stem cell transplantation in younger patients with mantle cell lymphoma (MCL). In elderly MCL patients the integration of bortezomib in frontline treatment strategies is very promising. Moreover, new therapeutic agents such as ibrutinib and idelalisib are tested successfully in clinical trials in relapsed indolent lymphoma.
Literatur
1.
Zurück zum Zitat Kimby E, Martinelli G, Ostenstad B, et al. Rituximab plus lenalidomide improves the complete remission rate in comparison with rituximab monotherapy in untreated follicular lymphoma patients in need of therapy. Primary endpoint analysis of the randomized Phase-2 Trial SAKK 35/10. Blood (ASH Annual Meeting Abstracts). 2014;124:Abstr 799. Kimby E, Martinelli G, Ostenstad B, et al. Rituximab plus lenalidomide improves the complete remission rate in comparison with rituximab monotherapy in untreated follicular lymphoma patients in need of therapy. Primary endpoint analysis of the randomized Phase-2 Trial SAKK 35/10. Blood (ASH Annual Meeting Abstracts). 2014;124:Abstr 799.
2.
Zurück zum Zitat Kahl B, Hong F, Williams M, et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. J Clin Oncol. 2014;32(28):3096–102. CrossRefPubMed Kahl B, Hong F, Williams M, et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. J Clin Oncol. 2014;32(28):3096–102. CrossRefPubMed
3.
Zurück zum Zitat Rummel M, Viardot A, Greil R, et al. Bendamustine plus rituximab followed by rituximab maintenance for patients with untreated advanced follicular lymphomas. Results from the StiL NHL 7–2008 Trial (MAINTAIN trial) (ClinicalTrials.gov Identifier: NCT00877214). Blood (ASH Annual Meeting Abstracts). 2014;124:Abstr 3052. Rummel M, Viardot A, Greil R, et al. Bendamustine plus rituximab followed by rituximab maintenance for patients with untreated advanced follicular lymphomas. Results from the StiL NHL 7–2008 Trial (MAINTAIN trial) (ClinicalTrials.gov Identifier: NCT00877214). Blood (ASH Annual Meeting Abstracts). 2014;124:Abstr 3052.
4.
Zurück zum Zitat Rummel M, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–10. CrossRefPubMed Rummel M, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–10. CrossRefPubMed
5.
Zurück zum Zitat Rummel M, Maschmeyer G, Ganser A, et al. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL)—7 year updated results from the StiL NHL1 study. Blood (ASH Annual Meeting Abstracts). 2014;124:Abstr 4407. Rummel M, Maschmeyer G, Ganser A, et al. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL)—7 year updated results from the StiL NHL1 study. Blood (ASH Annual Meeting Abstracts). 2014;124:Abstr 4407.
6.
Zurück zum Zitat Gopal K, Kahl B, De Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008–18. PubMedCentralCrossRefPubMed Gopal K, Kahl B, De Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008–18. PubMedCentralCrossRefPubMed
7.
Zurück zum Zitat Gopal K, Kahl B, De Vos S, et al. Mature follow up from a phase 2 study of pi3k-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma (iNHL). Blood (ASH Annual Meeting Abstracts). 2014;124:Abstr 1708. Gopal K, Kahl B, De Vos S, et al. Mature follow up from a phase 2 study of pi3k-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma (iNHL). Blood (ASH Annual Meeting Abstracts). 2014;124:Abstr 1708.
8.
Zurück zum Zitat De Vos S, Wagner-Johnston N, Coutre S, et al. Durable responses following treatment with the PI3K-delta inhibitor idelalisib in combination with rituximab, bendamustine, or both, in recurrent indolent non-Hodgkin lymphoma: Phase I/II results. Blood (ASH Annual Meeting Abstracts). 2014;124:Abstr 3063. De Vos S, Wagner-Johnston N, Coutre S, et al. Durable responses following treatment with the PI3K-delta inhibitor idelalisib in combination with rituximab, bendamustine, or both, in recurrent indolent non-Hodgkin lymphoma: Phase I/II results. Blood (ASH Annual Meeting Abstracts). 2014;124:Abstr 3063.
9.
Zurück zum Zitat De Vos S, Flowers C, Wang D, et al. The Bcl-2 Inhibitor ABT-199 (GDC-0199) in combination with bendamustine and rituximab in patients with relapsed or refractory non-Hodgkin’s lymphoma. Blood (ASH Annual Meeting Abstracts). 2014;124:Abstr 1722. De Vos S, Flowers C, Wang D, et al. The Bcl-2 Inhibitor ABT-199 (GDC-0199) in combination with bendamustine and rituximab in patients with relapsed or refractory non-Hodgkin’s lymphoma. Blood (ASH Annual Meeting Abstracts). 2014;124:Abstr 1722.
10.
Zurück zum Zitat Kluin-Nelemans H, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012;367(6):520–31. CrossRefPubMed Kluin-Nelemans H, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012;367(6):520–31. CrossRefPubMed
11.
Zurück zum Zitat Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab maintenance versus wait and watch after four courses of R-DHAP followed by autologous stem cell transplantation in previously untreated young patients with mantle cell lymphoma: first interim analysis of the Phase III prospective lyma trial, a Lysa Study. Blood (ASH Annual Meeting Abstracts). 2014;124:Abstr 146. Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab maintenance versus wait and watch after four courses of R-DHAP followed by autologous stem cell transplantation in previously untreated young patients with mantle cell lymphoma: first interim analysis of the Phase III prospective lyma trial, a Lysa Study. Blood (ASH Annual Meeting Abstracts). 2014;124:Abstr 146.
12.
Zurück zum Zitat Robak T, Huang H, Jin J, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Eng J Med. 2015;372(10):944–53. CrossRef Robak T, Huang H, Jin J, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Eng J Med. 2015;372(10):944–53. CrossRef
13.
Zurück zum Zitat Gressin R, Callanan M, Daguindau M, et al. Frontline therapy with the ribvd regimen elicits high clinical and molecular response rates and long PFS in elderly patients mantle cell lymphoma (MCL); final results of a prospective Phase II trial by the Lysa Group. Blood (ASH Annual Meeting Abstracts). 2014;124 Abstr 148. Gressin R, Callanan M, Daguindau M, et al. Frontline therapy with the ribvd regimen elicits high clinical and molecular response rates and long PFS in elderly patients mantle cell lymphoma (MCL); final results of a prospective Phase II trial by the Lysa Group. Blood (ASH Annual Meeting Abstracts). 2014;124 Abstr 148.
14.
Zurück zum Zitat Till B, Li H, Bernstein S, et al. Phase II Trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for previously untreated mantle cell lymphoma: SWOG 0601. Blood (ASH Annual Meeting Abstracts). 2014;124:Abstr 149. Till B, Li H, Bernstein S, et al. Phase II Trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for previously untreated mantle cell lymphoma: SWOG 0601. Blood (ASH Annual Meeting Abstracts). 2014;124:Abstr 149.
15.
Zurück zum Zitat Drach J, Huang H, Samoilova O, et al. Efficacy and safety of frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) Vs R-CHOP in a subset of newly diagnosed mantle cell lymphoma (MCL) patients (Pts) medically eligible for transplantation in the randomized Phase 3 LYM-3002 study (NCT00722137). Blood (ASH Annual Meeting Abstracts). 2014;124:Abstr 3064. Drach J, Huang H, Samoilova O, et al. Efficacy and safety of frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) Vs R-CHOP in a subset of newly diagnosed mantle cell lymphoma (MCL) patients (Pts) medically eligible for transplantation in the randomized Phase 3 LYM-3002 study (NCT00722137). Blood (ASH Annual Meeting Abstracts). 2014;124:Abstr 3064.
16.
Zurück zum Zitat Ruan J, Martin P, Shah B, et al. Sustained remission with the combination biologic doublet of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma: a multi-center Phase II study report. Blood (ASH Annual Meeting Abstracts). 2014;124:Abstr 625. Ruan J, Martin P, Shah B, et al. Sustained remission with the combination biologic doublet of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma: a multi-center Phase II study report. Blood (ASH Annual Meeting Abstracts). 2014;124:Abstr 625.
17.
Zurück zum Zitat Trneny M, Lamy T, Walewksi J, et al. Phase II randomized, multicenter study of lenalidomide vs best investigator’s choice in relapsed/refractory mantle cell lymphoma: results of the MCL-002 (SPRINT) study. Blood (ASH Annual Meeting Abstracts). 2014;124:Abstr 626. Trneny M, Lamy T, Walewksi J, et al. Phase II randomized, multicenter study of lenalidomide vs best investigator’s choice in relapsed/refractory mantle cell lymphoma: results of the MCL-002 (SPRINT) study. Blood (ASH Annual Meeting Abstracts). 2014;124:Abstr 626.
18.
Zurück zum Zitat Wang M, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–16. PubMedCentralCrossRefPubMed Wang M, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–16. PubMedCentralCrossRefPubMed
19.
Zurück zum Zitat Wang M, Rule S, Martin P, et al. Single-agent ibrutinib demonstrates safety and durability of response at 2 years follow-up in patients with relapsed or refractory mantle cell lymphoma: updated results of an international, multicenter, open-label Phase 2 study. Blood (ASH Annual Meeting Abstracts). 2014;124:Abstr 4453. Wang M, Rule S, Martin P, et al. Single-agent ibrutinib demonstrates safety and durability of response at 2 years follow-up in patients with relapsed or refractory mantle cell lymphoma: updated results of an international, multicenter, open-label Phase 2 study. Blood (ASH Annual Meeting Abstracts). 2014;124:Abstr 4453.
20.
Zurück zum Zitat Wang M, Hagemeister F, Westin J, et al. Ibrutinib and rituximab are an efficacious and safe combination in relapsed mantle cell lymphoma: preliminary results from a Phase II clinical trial. Blood (ASH Annual Meeting Abstracts). 2014;124:Abstr 672. Wang M, Hagemeister F, Westin J, et al. Ibrutinib and rituximab are an efficacious and safe combination in relapsed mantle cell lymphoma: preliminary results from a Phase II clinical trial. Blood (ASH Annual Meeting Abstracts). 2014;124:Abstr 672.
Metadaten
Titel
Indolent lymphoma at ASH 2014: new kids on the block (iDrugs)
verfasst von
MD Thomas Nösslinger
Publikationsdatum
01.09.2015
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2015
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-015-0211-y

Weitere Artikel der Ausgabe 3/2015

memo - Magazine of European Medical Oncology 3/2015 Zur Ausgabe